Шрифт:
Закладка:
4123
Carstens AJ. HRT prescriptions linked to 25 % of breast cancers in California. S Afr Med J. 2009;99(5):280. https://pubmed.ncbi.nlm.nih.gov/19588781/
4124
Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold “HRT.” PLoS Med. 2010;7(9):e1000335. https://pubmed.ncbi.nlm.nih.gov/20838656/
4125
Fugh-Berman A, Scialli AR. Gynecologists and estrogen: an affair of the heart. Perspect Biol Med. 2006;49(1):115–30. https://pubmed.ncbi.nlm.nih.gov/16489281/
4126
Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold “HRT.” PLoS Med. 2010;7(9):e1000335. https://pubmed.ncbi.nlm.nih.gov/20838656/
4127
Egilman AC, Kesselheim AS, Krumholz HM, Ross JS, Kim J, Kapczynski A. Confidentiality orders and public interest in drug and medical device litigation. JAMA Intern Med. 2020;180(2):292–9. https://pubmed.ncbi.nlm.nih.gov/31657836/
4128
Fugh-Berman A, Scialli AR. Gynecologists and estrogen: an affair of the heart. Perspect Biol Med. 2006;49(1):115–30. https://pubmed.ncbi.nlm.nih.gov/16489281/
4129
Tatsioni A, Siontis GCM, Ioannidis JPA. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med. 2010;25(9):914–9. https://pubmed.ncbi.nlm.nih.gov/20425148/
4130
Fugh-Berman A, Pearson C. The overselling of hormone replacement therapy. Pharmacotherapy. 2002;22(9):1205–8. https://pubmed.ncbi.nlm.nih.gov/12222561/
4131
Akesson A, Weismayer C, Newby PK, Wolk A. Combined effect of low-risk dietary and lifestyle behaviors in primary prevention of myocardial infarction in women. Arch Intern Med. 2007;167(19):2122–7. https://pubmed.ncbi.nlm.nih.gov/17954808/
4132
American Academy of Family Physicians. Clinical preventative service recommendation: hormone replacement therapy. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/hrt.html. Accessed Aug 2, 2022.; https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/hrt.html
4133
Fick DM, Semla TP, Steinman M, et al. American Geriatrics Society 2019 updated AGS Beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://pubmed.ncbi.nlm.nih.gov/30693946/
4134
Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update. J Am Coll Cardiol. 2011;57(12):1404–23. https://pubmed.ncbi.nlm.nih.gov/21325087/
4135
Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA. 2017;318(22):2224–33. https://pubmed.ncbi.nlm.nih.gov/29677309/
4136
ACOG Committee Opinion No. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121(6):1407–10. https://pubmed.ncbi.nlm.nih.gov/23812486/
4137
Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. https://pubmed.ncbi.nlm.nih.gov/15495039/
4138
Santoro N, Allshouse A, Neal-Perry G, et al. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study (KEEPS). Menopause. 2017;24(3):238–46. https://pubmed.ncbi.nlm.nih.gov/27779568/
4139
Marjoribanks J, Farquhar CM, Roberts H, Lethaby A. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women. Heart. 2018;104(2):93–5. https://pubmed.ncbi.nlm.nih.gov/28739806/
4140
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143. https://pubmed.ncbi.nlm.nih.gov/28093732/
4141
Marjoribanks J, Farquhar CM, Roberts H, Lethaby A. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women. Heart. 2018;104(2):93–5. https://pubmed.ncbi.nlm.nih.gov/28739806/
4142
Manson JE, Bassuk SS, Kaunitz AM, Pinkerton JV. The Women’s Health Initiative trials of menopausal hormone therapy: lessons learned. Menopause. 2020;27(8):918–28. https://pubmed.ncbi.nlm.nih.gov/32345788/
4143
Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28(1):81–90. https://pubmed.ncbi.nlm.nih.gov/20104432/
4144
Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978. https://pubmed.ncbi.nlm.nih.gov/15495039/
4145
Marjoribanks J, Farquhar CM, Roberts H, Lethaby A. Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women. Heart. 2018;104(2):93–5. https://pubmed.ncbi.nlm.nih.gov/28739806/
4146
Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–5. https://pubmed.ncbi.nlm.nih.gov/31995690/
4147
Chew F, Wu X. Sources of information influencing the state-of-the-science gap in hormone replacement therapy usage. PLoS One. 2017;12(2):e0171189. https://pubmed.ncbi.nlm.nih.gov/28158240/
4148
Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol. 2014;142:16–29. https://pubmed.ncbi.nlm.nih.gov/24176763/
4149
ClinCalc DrugStats database. The top 300 of 2019. ClinCalc.com. https://clincalc.com/DrugStats/Top300Drugs.aspx. Updated September 12, 2021. Accessed May 5, 2022.; https://clincalc.com/DrugStats/Top300Drugs.aspx
4150
Kling J. The strange case of Premarin. Mod Drug Discov. 2000;3(8):46–52. https://pubsapp.acs.org/subscribe/archive/mdd/v03/i08/html/kling.html
4151
Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–5. https://pubmed.ncbi.nlm.nih.gov/31995690/
4152
ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202–16. https://pubmed.ncbi.nlm.nih.gov/24463691/
4153
Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446–5. https://pubmed.ncbi.nlm.nih.gov/31995690/
4154
Brawley OW, O’Regan RM. Breast cancer screening: time for rational discourse. Cancer. 2014;120(18):2800–2. https://pubmed.ncbi.nlm.nih.gov/24925095/
4155
Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med. 2014;370(21):1965–7. https://pubmed.ncbi.nlm.nih.gov/24738641/
4156
Nelson AL. Controversies regarding mammography, breast self-examination, and clinical breast examination. Obstet Gynecol Clin North Am. 2013;40(3):413–27. https://pubmed.ncbi.nlm.nih.gov/24021250/
4157
Loh KP, Stefan MS, Friderici J, et al. Healthcare professionals’ perceptions and knowledge of the USPSTF guidelines on breast self-examination. South Med J. 2015;108(8):459–62. https://pubmed.ncbi.nlm.nih.gov/26280768/
4158
Welch HG. Screening mammography – a long run for a short slide? N Engl J Med. 2010;363(13):1276–8. https://pubmed.ncbi.nlm.nih.gov/20860510/
4159
Gigerenzer G. Women’s perception of the benefit of breast
